318 results on '"Bergenstal, Richard"'
Search Results
2. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report
3. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial
4. Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes
5. Time in Range, Time in Tight Range, and Average Glucose Relationships Are Modulated by Glycemic Variability: Identification of a Glucose Distribution Model Connecting Glycemic Parameters Using Real-World Data
6. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-Sectional Survey
7. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-Sectional Survey
8. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-Sectional Survey
9. Impact of insulin sensitivity and β-cell function over time on glycemic outcomes in the GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) Study: differential treatment effects of dual therapy.
10. Impact of insulin sensitivity and β-cell function over time on glycemic outcomes in the GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness) Study: differential treatment effects of dual therapy.
11. The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus
12. Roadmap to the Effective Use of Continuous Glucose Monitoring: Innovation, Investigation, and Implementation
13. Roadmaps to Continuous Glucose Monitoring’s Role in Transforming Diabetes Management
14. Two Years with a Tubeless AID System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes
15. Comprehensive Telehealth Model to Support Diabetes Self-Management
16. Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking
17. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes
18. Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE
19. Impact of severe hypoglycaemia requiring hospitalization on mortality in people with type 1 diabetes: A national retrospective observational cohort study
20. Biomarkers for the diagnosis of heart failure in people with diabetes: A consensus report from diabetes technology society
21. Glycemic Variability of Tirzepatide vs Insulin Degludec in People with Type 2 Diabetes (T2D) Using Continuous Glucose Monitoring (SURPASS-3 CGM)
22. Assessing time in range (TIR) with postprandial glucose (PPG)-focused titration of ultra rapid lispro (URLi) in patients (pts) with type 1 diabetes (T1D)
23. Advancing Diabetes Quality Measurement in the Era of Continuous Glucose Monitoring
24. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
25. Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
26. Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without Diabetes
27. Update on Measuring Ketones
28. Primary Care and Diabetes Technologies and Treatments
29. Assessment of the Glucose Management Indicator Using Different Sampling Durations
30. Continuous Glucose Monitoring Data as an Adjunct to A1C
31. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
32. The Relationship Between Percent Time Less Than 70 mg/dL and Percent Time Less Than 54 mg/dL Measured by Continuous Glucose Monitoring
33. A Comparison of Continuous Glucose Monitoring Estimated Hemoglobin A1c in Adults with Type 1 or Type 2 Diabetes
34. The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized Trial
35. A Roadmap to an Equitable Digital Diabetes Ecosystem
36. C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial
37. A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
38. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
39. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association
40. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice
41. Interindividual variability in average glucose‐glycated haemoglobin relationship in type 1 diabetes and implications for clinical practice
42. 88-OR: Discordance between Glucose Management Indicator (GMI) and A1C in Well-Controlled Type 1 Diabetes (T1D) and Nondiabetic Population
43. 652-P: Gaps Remain in Achieving Target T1D Glycemic Goals Despite Advanced Technologies
44. 728-P: Glycemic Variability of Tirzepatide vs. Insulin Degludec in People with Type 2 Diabetes Using Continuous Glucose Monitoring (SURPASS-3 CGM)
45. 105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial
46. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
47. A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
48. A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
49. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
50. Primary Care and Diabetes Technologies and Treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.